New Cancer Treatment Breakthroughs (2026 Update): The Biggest Advances Changing Cancer Care

Cancer research · Pancreatic cancer · KRAS

The trial reported a substantial improvement in overall survival and progression‑free survival with daraxonrasib.

Showing that targeting RAS signaling can produce clinically meaningful survival improvement in pancreatic ductal adenocarcinoma, a disease historically resistant to therapeutic progress.

Evidence level: Klinikai vizsgálat. Formális klinikai vizsgálati eredmény.

Original source

Related signals

• Pancreatic cancer
• Modified FOLFIRINOX improves survival compared to gemcitabine in resected pancreatic cancer
• Recent Advances in the Treatment of Pancreatic Cancer
• Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer
• EUROPAC Researching Hereditary Pancreatic Diseases